1. Home
  2. HURA vs SPCE Comparison

HURA vs SPCE Comparison

Compare HURA & SPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • SPCE
  • Stock Information
  • Founded
  • HURA 2009
  • SPCE 2017
  • Country
  • HURA United States
  • SPCE United States
  • Employees
  • HURA N/A
  • SPCE N/A
  • Industry
  • HURA
  • SPCE Transportation Services
  • Sector
  • HURA
  • SPCE Consumer Discretionary
  • Exchange
  • HURA Nasdaq
  • SPCE Nasdaq
  • Market Cap
  • HURA 193.8M
  • SPCE 197.9M
  • IPO Year
  • HURA N/A
  • SPCE N/A
  • Fundamental
  • Price
  • HURA $3.35
  • SPCE $6.72
  • Analyst Decision
  • HURA
  • SPCE Hold
  • Analyst Count
  • HURA 0
  • SPCE 6
  • Target Price
  • HURA N/A
  • SPCE $25.50
  • AVG Volume (30 Days)
  • HURA 77.7K
  • SPCE 2.0M
  • Earning Date
  • HURA 11-14-2024
  • SPCE 11-06-2024
  • Dividend Yield
  • HURA N/A
  • SPCE N/A
  • EPS Growth
  • HURA N/A
  • SPCE N/A
  • EPS
  • HURA N/A
  • SPCE N/A
  • Revenue
  • HURA N/A
  • SPCE $9,416,000.00
  • Revenue This Year
  • HURA N/A
  • SPCE N/A
  • Revenue Next Year
  • HURA N/A
  • SPCE N/A
  • P/E Ratio
  • HURA N/A
  • SPCE N/A
  • Revenue Growth
  • HURA N/A
  • SPCE 93.74
  • 52 Week Low
  • HURA $2.84
  • SPCE $5.27
  • 52 Week High
  • HURA $17.36
  • SPCE $54.60
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • SPCE 48.88
  • Support Level
  • HURA N/A
  • SPCE $6.53
  • Resistance Level
  • HURA N/A
  • SPCE $7.21
  • Average True Range (ATR)
  • HURA 0.00
  • SPCE 0.58
  • MACD
  • HURA 0.00
  • SPCE -0.03
  • Stochastic Oscillator
  • HURA 0.00
  • SPCE 30.42

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About SPCE Virgin Galactic Holdings Inc.

Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures advanced air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.

Share on Social Networks: